Immuron Ltd Logo

Immuron Ltd

Develops oral antibodies from bovine colostrum for digestive and immune health.

IMRN | US

Overview

Corporate Details

ISIN(s):
US45254U1016 (+1 more)
LEI:
Country:
United States of America
Address:
62 LYGON STREET, 3053 CARLTON, VICTORIA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of orally delivered, targeted polyclonal antibodies. The company's proprietary, patent-protected technology platform utilizes immunoglobulins (IgG) derived from hyper-immune bovine colostrum to address significant unmet medical needs. Immuron's primary focus is on gastrointestinal health, immune defense, and digestive disorders. Its portfolio of commercialized products includes Travelan®, for reducing the risk of travellers' diarrhoea; Protectyn®, for supporting gut and liver function; and ProIBS®, for the relief of symptoms related to Irritable Bowel Syndrome.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Immuron Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Immuron Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Immuron Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America GHRS
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GILEAD SCIENCES, INC. Logo
Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.
United States of America GILD

Talk to a Data Expert

Have a question? We'll get back to you promptly.